Compare Davita Inc (DVA) vs Figs Inc (FIGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Figs Inc — how do they compare? Davita Inc trades at $230.35 (market cap $14.92B), while Figs Inc trades at $9.79 (market cap $1.62B). The key difference: Davita Inc is far larger — about 9.2× Figs Inc's market cap, and Davita Inc is trading nearer its 52-week high, Figs Inc nearer its low. Which is the better fit depends on your goals.
| DVA | FIGS | |
|---|---|---|
Market Cap | $14.92B | $1.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $235.71 | $17.12 |
52-Week Low | $103.87 | $5.81 |
Enterprise Value | $27.47B | $1.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
FIGS trades at $10.00, down 0.4% on the day, with a bearish technical signal from moving averages but recent earnings beats. The company reported Q1 2026 revenue growth of 28% and raised full-year guidance, though net cash flow remains negative. Analyst consensus is a Buy with a $19.50 price target, implying significant upside from current levels.
The outlook is mixed: strong fundamentals and growth prospects support the bull case, but valuation is rich at a P/E of 45.45, and margin pressures from tariffs and spending pose risks. The stock's performance hinges on execution of global expansion and cost management amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →
